ALDX Stock Analysis: Buy, Sell, or Hold?
ALDX - Aldeyra Therapeutics, Inc.
$2.02
-0.03 (-1.46%)
▼
5d:
+14.77%
30d:
+27.04%
90d:
-9.42%
HOLD
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When ALDX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: ALDX is 8.6% above its trading range ($1.86). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: ALDX is 8.6% above its trading range ($1.86). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: ALDX is currently trading at $2.02, which is considered extended relative to its 30-day fair value range of $1.60 to $1.86. From a valuation perspective, the stock is trading at a discount (Forward PE: -11.2) compared to its historical average (12.8). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, ALDX is in a strong downtrend. Immediate support is located at $1.65, while resistance sits at $2.21.
Market Sentiment: ALDX has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $7.60 (+276.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ALDX is in a strong downtrend. Immediate support is located at $1.65, while resistance sits at $2.21.
Market Sentiment: ALDX has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $7.60 (+276.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.60 -
$1.86
Company Quality Score
62/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
61.9%
All Signals
- BEARISH: Price extended above range (+8.6% above its trading range)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 276.2% below Wall St target ($7.60)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- CAUTION: Extended 8.6% above its trading range - wait for pullback
Trading Range Analysis
30-Day Trading Range
$1.60 -
$1.86
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.65
Resistance Level
$2.21
Current Trend
Strong Downtrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-11.22
Wall Street Target
$7.60
(+276.2%)
PE vs Historical
-11.2 vs 12.8
CHEAP
Share & Embed Analysis
Last updated: June 24, 2026 5:45 AM ET
Data refreshes hourly during market hours. Next update: 6:45 AM
Data refreshes hourly during market hours. Next update: 6:45 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ALDX showing a specific setup today?
Insider Activity (6 Months)
2
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Richard Douglas
BUY
70000 shares
2026-03-19
Michael Alfieri
BUY
5000 shares
2026-03-18
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 65 BUY |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$436 | 54 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 67 BUY |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 54 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 59 HOLD |
